Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond

References

• World Health Organization. Malaria eradication: benefits, future scenarios and feasibility: a report of the Strategic Advisory group on malaria eradication [Internet]. Geneva: World Health Organization; 2020 [accessed 2023 Nov 22]. Available from: https://apps.who.int/iris/handle/10665/331795.
   Google Scholar
• Tizifa TA, Kabaghe AN, McCann RS, et al. Prevention efforts for malaria. Curr Trop Med Rep. 2018;5(1):41–50. doi: 10.1007/s40475-018-0133-y
   PubMedGoogle Scholar
• Holmes KK, Bertozzi S, Bloom BR, et al. editors. Chapter 13: malaria control. Disease control priorities, third edition: major infectious diseases. [Internet]. The World Bank; 2017 [accessed 2023 Nov 10]. Available from: http://elibrary.worldbank.org/doi/book/10.1596/978-1-4648-0524-0
   Google Scholar
• World Health Organization. World malaria report 2023 [Internet]. Geneva; 2023 [cited 2023 Dec 1]. Available from: https://iris.who.int/bitstream/handle/10665/374472/9789240086173-eng.pdf?sequence=1
   Google Scholar
• World Health Organization. Malaria vaccines: preferred product characteristics and clinical development considerations [Internet]. Geneva: World Health Organization; 2022 [accessed 2023 Nov 22]. Available from: https://apps.who.int/iris/handle/10665/362694
   Google Scholar
• Beeson JG, Kurtovic L, Valim C, et al. The RTS,S malaria vaccine: Current impact and foundation for the future. Sci Transl Med. 2022;14(671):eabo6646. doi: 10.1126/scitranslmed.abo6646
   PubMed Web of Science ®Google Scholar
• Chandramohan D, Zongo I, Sagara I, et al. Seasonal malaria vaccination with or without seasonal malaria chemoprevention. N Engl J Med. 2021;385(11):1005–1017. doi: 10.1056/NEJMoa2026330
   PubMed Web of Science ®Google Scholar
• Cairns M, Barry A, Zongo I, et al. The duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01E vaccination and seasonal malaria chemoprevention versus either intervention given alone. BMC Med. 2022;20(1):1–15. doi: 10.1186/s12916-022-02536-5
   PubMed Web of Science ®Google Scholar
• World Health Organization. Slide Decks for Strategic Advisory group of experts on immunization 20-23 March 2023 [accessed 2023 Nov 22]. Available from: https://terrance.who.int/mediacentre/data/sage/SAGE_Slidedeck_March_2023.pdf
   Google Scholar
• World Health Organization. Framework for the allocation of limited malaria vaccine supply [Internet]. 2022 [accessed 2023 Nov 22]. Available from: https://www.who.int/publications/m/item/framework-for-allocation-of-limited-malaria-vaccine-supply
   Google Scholar
• Bawa J, Furur E, Asante KP, et al. Symposium 72: evidence and lessons learned from the malaria vaccine implementation program (2019-2023). Chicago (IL): American Society of Tropical Medicine and Hygiene Annual Meeting; 2023.
   Google Scholar
• R21/Matrix-MTM malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana [Internet]. 2023 [accessed 2023 Nov 22]. Available from: https://www.ox.ac.uk/news/2023-04-13-r21matrix-m-malaria-vaccine-developed-university-oxford-receives-regulatory
   Google Scholar
• WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization [Internet]. [accessed 2023 Nov 10]. Available from: https://www.who.int/news/item/02-10-2023-who-recommends-r21-matrix-m-vaccine-for-malaria-prevention-in-updated-advice-on-immunization
   Google Scholar
• Datoo MS, Dicko A, Tinto H, et al. A phase III randomised controlled trial evaluating the malaria vaccine candidate R21/Matrix-MTM in African children [Internet]. Rochester (NY); 2023 [accessed 2023 Nov 20]. Available from: https://papers.ssrn.com/abstract=4584076
   Google Scholar
• Five things you need to know about the new R21 malaria vaccine [Internet]. 2023 [accessed 2023 Nov 22]. Available from: https://www.gavi.org/vaccineswork/five-things-you-need-know-about-new-r21-malaria-vaccine
   Google Scholar
• Matarazzo L, Bettencourt PJG. mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV. Front Immunol. 2023;14:1172691
   PubMed Web of Science ®Google Scholar
• Nunes-Cabaço H, Moita D, Prudêncio M. Five decades of clinical assessment of whole-sporozoite malaria vaccines. Front Immunol. 2022;13:977472. doi: 10.3389/fimmu.2022.977472
   PubMed Web of Science ®Google Scholar
• Richie TL, Church LWP, Murshedkar T, et al. Sporozoite immunization: innovative translational science to support the fight against malaria. Expert Rev Vaccines. 2023;22(1):964–1007. doi: 10.1080/14760584.2023.2245890
   PubMed Web of Science ®Google Scholar
• Langowski MD, Khan FA, Savransky S, et al. Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum. NPJ Vaccines. 2022;7(1):13. doi: 10.1038/s41541-022-00430-y
   PubMed Web of Science ®Google Scholar
• Nema S, Nitika N. Monoclonal antibody: future of malaria control and prevention. Trans R Soc Trop Med. 2023;trad027(9):673–674. doi: 10.1093/trstmh/trad027
   Google Scholar
• Kisalu NK, Idris AH, Weidle C, et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med. 2018;24(4):408–416. doi: 10.1038/nm.4512
   PubMed Web of Science ®Google Scholar
• Wang LT, Pereira LS, Flores-Garcia Y, et al. A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity. 2020;53(4):733–744.e8. doi: 10.1016/j.immuni.2020.08.014
   PubMed Web of Science ®Google Scholar
• Kayentao K, Ongoiba A, Preston AC, et al. Safety and efficacy of a monoclonal antibody against malaria in Mali. N Engl J Med. 2022;387(20):1833–1842. doi: 10.1056/NEJMoa2206966
   PubMed Web of Science ®Google Scholar